|Bid||21.19 x 100|
|Ask||0.00 x 0|
|Day's range||24.80 - 25.79|
|52-week range||24.80 - 55.95|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.50|
Investors in Medicines Company (MDCO) need to pay close attention to the stock based on moves in the options market lately.
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
The Medicines Company today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin® IV, and the assumption by Melinta of all royalty, ...
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the successful completion of its previously announced acquisition of The Medicines Company’s (NASDAQ:MDCO) infectious disease business. “The completion of this acquisition marks yet another milestone in what has been a very exciting time for Melinta as we focus on creating the leading pure-play antibiotics company,” said Dan Wechsler, President and CEO of Melinta.
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
The Medicines Company today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at 8:30 a.m., Pacific Time, at The Westin St.
The Medicines Company today announced that it will host an Investor Day on Tuesday, January 23, 2018, from 10:00 a.m. to 12:30 p.m., Eastern Time, in New York City.
Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy ...
Sarissa Capital Management last week made nearly $15 million in stock purchases. Sarissa, a hedge fund that specializes in drug developers, added to positions in Biogen (BIIB) and Medicines (MDCO). On Nov. 28 and 29 the fund bought 30,000 shares of Biogen for $9.52 million, or $317.36 each.
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Shares of Medicines Co. dove to a 21-month low after the biotech sold its infectious diseases unit for $270 million.
The Medicines Co. said Wednesday it has agreed to sell its infectious disease unit to Melinta Therapeutics Inc. for $270 million in upfront consideration, guaranteed payments of $215 million in cash and ...
The Medicines Company today announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. for $270 million in upfront consideration and guaranteed payments , tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment ...
The Medicines Company today announced that its Board of Directors has appointed Fredric N. Eshelman, PharmD., the Company’s current Chairman of the Board, to the newly created position of Executive Chairman, and Geno Germano, a pharmaceutical industry executive with over 30 years of leadership experience, as a new, independent Director of the Company.
The Medicines Company's CEO, Dr. Clive Meanwell, believes that inclisiran can be a very successful drug at a much lower price than Repatha and Praluent.
The Medicines Company today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities.
The Medicines Company will host a conference call on Wednesday, October 25, 2017, at 8:30 a.m., Eastern Time, to discuss its third-quarter 2017 financial results and operational developments.
Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris......
In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
The Medicines Company today announced that new data from its TANGO II study of VABOMERE will be presented this week at IDWeek 2017 in San Diego.